Check point inhibition in organ fibrosis
AssigneeVanderbilt University
InventorWonder P. Drake
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for treating pulmonary fibrosis with PD1 blockade, STAT3 inhibitors, IL-17 inhibitors, and/or TGFβ-1 inhibitors.
Claims18
A method of treating pulmonary disease or collagen-1 production in a subject with a pulmonary disease comprising administering to the subject an agent that reduces STAT3 production or activation.
A method of creating a prognosis for a subject with a pulmonary disease comprising obtaining a tissue sample from a subject, isolating the TGFβ+PD1+CD4 T cells (TH17 cells), measuring the number of TH17 CD4+ T cells or the IL-17 expression levels relative to a control, wherein an increase in the number of TH17 cells or an increase in IL-17 expression levels relative to a control indicates a more aggressive disease and decreased survival chances for the subject.
(canceled)
(canceled)
A method of creating a prognosis for a subject with a pulmonary disease comprising obtaining a tissue sample from a subject, isolating the TGFβ+PD1+CD4 T cells (TH17 cells), assaying for single nucleotide polymorphisms (SNPs) in the STAT3 gene, IL-17RA gene, IL-17D gene, ERAP2 gene, PDCD1 gene, and/or TGF-β1 gene, wherein the presence of an assayed SNP in the STAT3 gene, IL-17RA gene, PDCD1 gene, or TGF-β1 gene indicate an increased risk of disease progression, the presence of a assayed SNP in the IL-17D gene indicates increased risk of persistence, and the presence of an assayed SNP in the ERAP2 gene indicates increased risk of disease progression and persistence.
A method of treating pulmonary disease in a subject comprising administering to the subject an inhibitor IL-17A and/or TGFβ-1.
(canceled)
Dependencies are inferred from the claim text.